Bile acids, synthesized in hepatocytes, are secreted into the biliary system to aid in lipid digestion. They transit through a network of ducts lined with BECs, whose role extends far beyond simple conduits. These epithelial cells form a tightly regulated barrier that maintains ductal integrity, preventing toxic BA spillover into the surrounding liver parenchyma. Dysfunction in this barrier has long been known to precipitate BA-induced damage, inflammation, and eventually fibrosis—a pathological scarring process that disrupts liver architecture and compromises function. However, the cellular mechanisms underlying how BECs sustain barrier function and restrain fibrogenesis have remained elusive—until now.

The team employed a sophisticated combination of mouse genetic models, computational gene regulation analyses, and validation with human liver samples to dissect this regulatory axis. They found that FXR, a nuclear receptor traditionally recognized for its role in systemic bile acid sensing and metabolic control, is highly expressed in BECs. Significantly, FXR acts as a transcriptional activator of YAP, a potent regulator of cell proliferation and tissue repair pathways. This FXR-driven activation of YAP enables BECs to maintain robust adhesive properties crucial for the integrity of the biliary barrier, effectively preventing the leakage of bile acids into parenchymal tissue.

Loss-of-function experiments using mouse models with FXR or YAP selectively ablated in BECs uncovered a dramatic cascade of pathological events, highlighting the indispensability of this signalling duo. Without FXR or YAP, BECs undergo profound phenotypic changes characterized by activation of β-catenin signalling and a mesenchymal-like transition. These changes provoke abnormal BEC proliferation and a breakdown of the bile duct barrier, resulting in unchecked bile acid diffusion, hepatic stellate cell activation, and the establishment of a fibrotic microenvironment. This pathological sequence critically accelerates fibrogenesis and pushes liver injury toward irreversible cirrhosis.

An especially compelling aspect of this study is its translational relevance. Human liver biopsies demonstrated a striking correlation between diminished FXR–YAP signalling within BECs and the severity of fibrosis, cementing the clinical significance of these findings. This implies that weakened FXR–YAP pathways could serve as biomarkers for progressive liver disease and potentially predict patient outcomes. Moreover, the group’s clinical insights raise caution against the use of obeticholic acid (OCA), a synthetic FXR agonist currently employed in treating certain cholestatic liver diseases. While OCA typically activates FXR to restore bile acid homeostasis, in the context of FXR-deficient BECs, its administration exacerbated fibrotic progression, uncovering a paradoxical effect that may inform future therapeutic strategies.

Mechanistically, this research highlights how bile acids intrinsically “reprogram” BECs via FXR to engage YAP-dependent transcriptional networks. This dynamic programming preserves epithelial identity, reinforcing junctional adhesion complexes that fortify the ductal wall. Concurrently, FXR–YAP signalling curtails β-catenin-mediated mesenchymal transformation, which otherwise endangers biliary architecture and promotes fibrotic niche formation. This nuanced interplay ensures that BECs not only provide structural support but serve as active regulators of tissue homeostasis, engaging in crosstalk with hepatic stellate cells and the broader liver microenvironment.

The implications of this study extend well beyond the specialized realm of bile duct biology. By positioning FXR–YAP as a central molecular axis in epithelial maintenance and fibrosis prevention, these findings invite deeper exploration into related pathways involved in other epithelial tissues subject to fibrogenic insults. Given the notorious difficulty in treating liver fibrosis once established, unravelling endogenous mechanisms that halt fibrogenesis upstream offers a beacon of hope for more effective, targeted interventions that restore normal tissue architecture rather than merely mitigating symptoms.

Future investigations spurred by these discoveries will likely focus on identifying small molecules or biologics that potentiate the FXR–YAP axis specifically within BECs, potentially offering novel antifibrotic therapies with enhanced precision and safety profiles. Additionally, understanding how BA dysregulation influences BEC signalling in chronic liver diseases such as primary sclerosing cholangitis, non-alcoholic steatohepatitis, and cholangiocarcinoma may unlock new paradigms for managing these conditions.

This study also underscores the remarkable plasticity of epithelial cells in the liver, highlighting their dual capacity to act as both damage responders and guardians of tissue integrity. The observation that epithelial cells translate metabolic cues from bile acids into structural and transcriptional programs reshapes our conceptual framework of liver biology, reinforcing the integrative nature of metabolism, signalling, and cellular identity.

In summary, the elucidation of the FXR–YAP signalling pathway in BECs represents a major advance in hepatology, revealing how these specialized epithelial cells autonomously safeguard the bile duct barrier and modulate the fibrogenic cascade. By intricately balancing adhesion, proliferation, and mesenchymal transition, FXR–YAP ensures that bile acid homeostasis is maintained and fibrotic progression curtailed. The clinical and therapeutic ramifications of this discovery herald a promising frontier for liver disease research, with the potential to pivot current treatment paradigms toward preserving endogenous tissue homeostasis and preventing cirrhosis before its deadly culmination.

Subject of Research: Biliary epithelial cell biology, bile acid regulation, liver fibrosis, FXR–YAP signalling pathways.

Article Title: FXR–YAP signalling maintains biliary epithelial cell identity and preserves liver homeostasis.

Article References:
Sánchez-Sánchez, P., Wang, Z., Zagorac, S. et al. FXR–YAP signalling maintains biliary epithelial cell identity and preserves liver homeostasis. Nat Metab (2026). https://doi.org/10.1038/s42255-026-01521-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-026-01521-z

Central to this discovery is the bile duct, a complex tubular network whose cells, known as biliary epithelial cells (BECs), have conventionally been viewed as mere conduits for bile transport. The CNIO research team challenges this simplistic perception by demonstrating that BECs are dynamic regulatory units, actively maintaining the liver’s internal environment and defending against injury-induced fibrosis. The study identifies a critical signaling axis within BECs—the FXR–YAP pathway—as quintessential for sustaining the structural integrity of bile ducts and for regulating cellular proliferation and barrier functions.

Under physiological conditions, the Farnesoid X receptor (FXR), a bile acid-sensitive nuclear receptor expressed in BECs, detects and binds bile acids coursing through the bile ducts. This binding stimulates a downstream cascade culminating in the activation of the Yes-associated protein (YAP), a transcriptional coactivator that modulates gene expression linked to cell adhesion and proliferation. YAP induction promotes the expression of adhesion molecules that tightly seal adjacent BECs, forming a robust barrier that prevents bile acid leakage into the liver parenchyma. Concurrently, YAP serves a regulatory role curbing excessive biliary cell proliferation by orchestrating the activity of other proteins essential for maintaining cellular homeostasis.

The study elucidates how disruption of this FXR–YAP axis compromises biliary integrity and fosters fibrotic pathology. In certain genetic and disease contexts, FXR expression or function is diminished, leading to uncontrolled proliferation of BECs and weakening of cell junctions. This breakdown in barrier function permits bile acids—potent detergents and signaling molecules—to infiltrate the hepatic parenchyma, inciting damage to hepatocytes and activating hepatic stellate cells. These stellate cells transition into a fibrogenic state, secreting extracellular matrix components that accumulate as scar tissue, driving the onset and progression of liver fibrosis.

Leveraging a multifaceted methodological approach encompassing genetically engineered murine models, computational biology, and histological examination of human liver biopsies, the researchers establish a direct causal link between FXR loss in BECs and accelerated hepatic fibrogenesis and cirrhosis. Importantly, the work entails the utilization of the first genetically modified mouse model recapitulating cirrhosis, enabling in-depth mechanistic insights and translational relevance for human disease.

These findings bear significant translational potential, particularly regarding therapeutic strategies targeting the FXR pathway. Current clinical management of certain cholestatic liver diseases involves the administration of obeticholic acid (OCA), a semi-synthetic bile acid analog designed to activate FXR and mitigate fibrosis. However, paradoxical exacerbation of fibrosis in some patients on OCA therapy has perplexed clinicians. The CNIO study provides a plausible mechanistic explanation: in patients exhibiting impaired FXR function within biliary epithelial cells, OCA fails to elicit the protective YAP response, potentially aggravating bile duct barrier dysfunction and fibrosis.

The clinical ramifications extend to patient stratification and precision medicine. Recognizing heterogeneous FXR activity among individuals could guide the selection of candidates likely to benefit from FXR agonist therapies while avoiding adverse outcomes in those prone to deleterious responses. Furthermore, the research advocates for the development of novel agents or combination therapies aimed at restoring the FXR–YAP balance, reinforcing bile duct barriers, and preventing fibrotic sequelae.

Beyond therapeutic considerations, this study upends the canonical understanding of bile ducts’ role in hepatic physiology. The revelation that BECs are not passive channels but active cellular gatekeepers modulating bile acid signaling and liver tissue integrity reframes how researchers conceptualize liver homeostasis and injury response. This paradigm shift opens new research avenues exploring how bile duct cellular dynamics influence broader liver pathologies, including cancer initiation and progression.

The discovery also highlights the delicate interplay between signaling pathways in complex organ systems. The FXR–YAP axis exemplifies how nuclear receptor-mediated transcriptional programs intersect with mechanotransductive pathways to sustain cellular architecture and prevent disease. Deciphering such crosstalk provides a blueprint for understanding other fibrosis-related conditions beyond the liver, underscoring the universality of these molecular principles.

Funding for this research was provided by the Spanish Department of Science Innovation and Universities through the State Research Agency, the European Union’s European Regional Development Funds, Madrid’s Regional Government, and several prestigious foundations including AECC, Fundación BBVA, and Fundación Ramón Areces. Supported by the Carlos III Health Institute and embedded within the IDIFFER excellence network, this work exemplifies the collaborative spirit driving cutting-edge biomedical science.

The National Cancer Research Centre (CNIO) stands at the forefront of oncological and translational medicine in Spain and Europe, hosting multidisciplinary teams committed to unraveling complex biological problems. Through rigorous scientific inquiry exemplified by this study, the CNIO continues to make impactful contributions that promise to transform patient care and deepen our understanding of human diseases.

In conclusion, the CNIO’s elucidation of the FXR–YAP signaling mechanism in biliary epithelial cells not only advances foundational knowledge of liver biology but also presents actionable insights for combating liver fibrosis and its devastating consequences. As this research moves towards clinical application, it heralds a new era of precision hepatology where molecular diagnostics and targeted therapeutics converge to improve patient outcomes in chronic liver disease.

Subject of Research: Human tissue samples
Article Title: FXR–YAP signalling maintains biliary epithelial cell identity and preserves liver homeostasis
News Publication Date: 28-Apr-2026
Web References: DOI link
Image Credits: Fibrosis (red) in parenchymal liver cells (blue) as a response to cellular injury. / Paula Sánchez. CNIO
Keywords: Liver fibrosis, Biliary epithelial cells, FXR receptor, YAP signaling, Bile duct integrity, Liver cirrhosis, Obeticholic acid, Bile acid leakage, Hepatic stellate cells, Fibrogenesis, Precision medicine, Chronic liver disease